SCHEMBL4637575

SCHEMBL4637575

CC(C)NS(=O)(=O)Cc1cccc(CN)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
ADAMTS4 O75173 1/20 0.42
HTR6 P50406 1/20 0.41
LOXL2 Q9Y4K0 2/20 0.41
SLC1A3 P43003 1/20 0.40
SLC1A2 P43004 1/20 0.40
SLC1A1 P43005 1/20 0.40
PRMT6 Q96LA8 1/20 0.39
NOS3 P29474 2/20 0.38
NOS1 P29475 2/20 0.38
NOS2 P35228 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CYP3A4 P08684 1/20 0.38
NFKB1 P19838 1/20 0.38
PNMT P11086 1/20 0.38
ENPP2 Q13822 1/20 0.38
F2 P00734 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5121672 0.86 PSIP1 (0.44) ALDH1A1MEN1HTTKMT2ALOXL2
SCHEMBL4433007 0.84 MEN1 (0.43) ALDH1A1MEN1HTTKMT2ASLC1A3
SCHEMBL16000106 0.82 ACLY (0.46) ALDH1A1MEN1HTTKMT2A
SCHEMBL2640501 0.81 HTR6 (0.44) ALDH1A1HTR6LOXL2PRMT6NOS3
SCHEMBL19808630 0.81 MEN1 (0.41) ALDH1A1MEN1HTTKMT2AADAMTS4
SCHEMBL21886080 0.81 TAAR1 (0.44) ALDH1A1MEN1HTTKMT2AADAMTS4
SCHEMBL16000102 0.81 CNR1 (0.53) ALDH1A1MEN1HTTKMT2AADAMTS4
SCHEMBL19808137 0.80 CYP19A1 (0.43) ALDH1A1MEN1HTTKMT2A
SCHEMBL19808468 0.80 RECQL (0.41) ALDH1A1MEN1HTTKMT2ASLC1A3
SCHEMBL1998707 0.79 ALDH1A1 (0.63) ALDH1A1MEN1HTTKMT2ASLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937652-B1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMA INC (US) 2014-07-30 EP disclosed
US-8202863-B2 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease AVENTIS PHARMACEUTICALS INC. (US) 2012-06-19 US disclosed
US-20080227782-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2008-09-18 US disclosed
EP-1937652-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS Aventis Pharmaceuticals Inc. (US) 2008-07-02 EP disclosed
WO-2007041634-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227782-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, LTC4S ALDH1A1 871/4885MEN1 4523/4885HTT 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.